5-AZA-2'-deoxycytidine in cancer immunotherapy: a mouse to man story.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

8 citing papers in PubMed.

1. Targeting Epigenetic Modifications in Uveal Melanoma.International journal of molecular sciences · 2020
   Review
2. Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide).Cancer chemotherapy and pharmacology · 2014
   Article
3. Epigenetic remodelling of gene expression profiles of neoplastic and normal tissues: immunotherapeutic implications.British journal of cancer · 2012
   Article
4. The biology of cancer testis antigens: putative function, regulation and therapeutic potential.Molecular oncology · 2011
   Article
5. Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study.Cancer · 2010
   Article
6. Efficacy of a 3-day, low-dose treatment with 5-azacytidine followed by donor lymphocyte infusions in older patients with acute myeloid leukemia or chronic myelomonocytic leukemia relapsed after allografting.Bone marrow transplantation · 2010
   Article
7. Real-time PCR analysis of genes encoding tumor antigens in esophageal tumors and a cancer vaccine.Cancer immunity · 2009
   Article
8. HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance.Oncogene · 2008
   Review

Corrections and comments

• Comment on
  De novo induction of a cancer/testis antigen by 5-aza-2'-deoxycytidine augments adoptive immunotherapy in a murine tumor model.2006

Authors and funding

6 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as